On the Surface, a Smarter Approach

Treating patients systemically can lead to unwanted effects in the body owing to a lack of specificity and the need for high doses. At Pulmocide, we aim to deliver novel antifungal treatments delivered easily and directly to the lung to maximize efficacy and minimize adverse effects.

More
Novel inhaled respiratory medicine development pipeline.

We are developing novel, potent first-in-class anti-infective agents for delivery by inhaled administration for life-threatening lower respiratory infections.

more

Management Team

Investors